Europe Genetic Testing Market Size, Share & Trends Analysis Report By Technique (Polymerase chain reaction (PCR), Next Generation Sequencing, Cytogenetics, Microarrays, Others), By Application (Ancestry & Ethnicity, Traits Screening, Genetic Disease Carrier Status, New Baby Screening, Others), By Product (Consumables, Equipment, Software & Services), By End Use (Hospitals & Clinics, Diagnostic Laboratories, Others) and By Country (U.K., Germany, France, Spain, Italy, Russia, Nordic, Benelux, Rest of Europ) Forecasts, 2026-2034

Market Overview

Europe genetic testing market size was valued at USD 3.96 Billion in 2025 and is projected to reach from USD 4.37 Billion in 2026 to USD 9.65 Billion by 2034, growing at a CAGR of 10.4% during the forecast period 2026-2034.

A genetic test is a type of medical testing that is carried out with the purpose of determining whether or not there have been any alterations to the chromosomal structure or the DNA sequence. Either the gene included within the DNA sequence can be directly recognised through the sequencing process or indirectly identified through a variety of methods of genetic testing. The use of genetic testing in the diagnosis of rare diseases and the practise of customised medicine is expanding at a rapid rate.

In addition, the growing number of technology improvements that have occurred over the course of the previous few years have made various prospects for market development available. The rapid expansion of the market is being aided by a number of factors, including an increase in the incidence of chronic illnesses and the creation of specialised testing kits for specialised treatment areas. According to the World Population Prospects 2020 Highlights published by the United Nations, there will be more than 1.5 billion people over the age of 65 years by the year 2050, which is an increase from 727 million in the year 2020. Because of the rising number of elderly people and their increased risk of developing chronic illnesses, there has been an uptick in the need for preventative diagnostics, in particular genetic testing.

The increased attention that governments of various countries are placing on regulating genetic testing and raising knowledge about them has effectively resulted in a speedier acceptance of these tests all around the world. Increased spending on research and development, along with large firms' already established footholds in the market, has made it difficult for new companies to break into the industry. Maintaining a competitive advantage in the market requires a number of critical characteristics to be satisfied, including innovation in product design, improvement in quality, and strong distribution relationships. For instance, in August 2020, Ricoh Company Ltd. and DNA Chip Research Inc. produced RICOH Standard DNA Series EGFR mutation Type001, which is a reference DNA plate to be utilised in the blood-based genetic testing in the diagnosis of lung cancer. This plate is intended to be used by many companies.

Europe Genetic Testing Market Segmental Analysis

By Technique

The Europe genetic testing market is segmented by technique into polymerase chain reaction (PCR), next generation sequencing, cytogenetics, microarrays, and others. Polymerase chain reaction (PCR) remains widely utilized for targeted genetic analysis because of its established laboratory applications and compatibility with various diagnostic workflows. Next generation sequencing is gaining importance as healthcare providers increasingly seek comprehensive analysis of genetic variants across multiple genes or broader genomic regions. Cytogenetics continues to support the identification of chromosomal abnormalities, while microarrays enable simultaneous analysis of numerous genetic markers. The others category includes additional molecular testing technologies used for specialized diagnostic and research applications.

Increasing adoption of precision medicine, expanding genomic research, and improvements in molecular diagnostic infrastructure are supporting the use of advanced genetic testing techniques across Europe. Next generation sequencing is benefiting from its ability to generate detailed genomic information, while PCR remains relevant because of its established use, targeted testing capabilities, and integration into routine laboratory procedures. Advancements in automation, sequencing platforms, bioinformatics, and laboratory workflows are further improving testing efficiency. However, differences in healthcare budgets, testing reimbursement, regulatory requirements, and access to specialized technologies across European countries can influence the pace of adoption.

Request Customizationto receive a tailored report.

By Application

The Europe genetic testing market is categorized by application into ancestry & ethnicity, traits screening, genetic disease carrier status, new baby screening, and others. Ancestry and ethnicity testing is supported by growing consumer interest in family origins and genetic heritage, while traits screening provides individuals with information related to inherited characteristics and biological features. Genetic disease carrier status testing has an important role in identifying individuals who may carry variants associated with inherited conditions, particularly in reproductive and family-planning settings. New baby screening is another significant application, as genetic testing can assist in identifying certain inherited or metabolic conditions at an early stage and enable timely clinical assessment.

The others category covers additional applications such as genetic risk assessment, reproductive testing, inherited disease evaluation, and personalized healthcare. Increasing awareness of hereditary conditions and the growing integration of genomic information into healthcare are creating opportunities across these applications. European healthcare systems and research institutions are also contributing to the adoption of genetic testing through advancements in precision medicine and population-level genomic initiatives. At the same time, data privacy, ethical considerations, regulatory requirements, testing costs, and the interpretation of genetic results remain important factors shaping consumer and clinical adoption throughout the region.

By Product

The Europe genetic testing market is segmented by product into consumables, equipment, and software & services. Consumables include reagents, test kits, sample preparation materials, cartridges, and other laboratory supplies required for genetic analysis. Demand for these products is closely associated with the increasing volume of tests performed across clinical laboratories, hospitals, research facilities, and specialized testing centers. Equipment encompasses PCR systems, sequencing instruments, microarray platforms, and other analytical devices used to process genetic samples. Investments in laboratory modernization and the increasing adoption of molecular diagnostic technologies are supporting demand for advanced genetic testing equipment across Europe.

Software & services are becoming increasingly important as genetic testing produces large quantities of complex genomic information requiring efficient processing, interpretation, storage, and management. Bioinformatics software, genomic data platforms, laboratory information systems, genetic counseling, testing services, and data interpretation solutions help convert test results into meaningful clinical or research insights. Increasing use of next generation sequencing is further strengthening the need for advanced computational capabilities. Market development across Europe is influenced by laboratory investments, technology costs, data-management requirements, regulatory standards, and the availability of skilled professionals. Continued development of integrated testing and analysis platforms is expected to create further opportunities within this segment.

By End Use

The Europe genetic testing market is divided by end use into hospitals & clinics, diagnostic laboratories, and others. Hospitals and clinics represent important end users because genetic testing is increasingly utilized in areas such as inherited disease diagnosis, prenatal care, reproductive health, oncology, and personalized medicine. The integration of genomic information into clinical decision-making is encouraging healthcare providers to incorporate genetic testing into selected diagnostic and treatment pathways. Diagnostic laboratories are another major end-use group, performing genetic analyses for hospitals, physicians, researchers, and individual patients. Expansion of specialized laboratory networks and investment in advanced molecular testing platforms are supporting greater testing capacity across Europe.

The others category includes research institutions, academic organizations, pharmaceutical companies, biotechnology firms, and other facilities involved in genetic research and specialized testing activities. These end users utilize genetic testing for drug discovery, clinical research, biomarker identification, population genomics, and the development of targeted therapies. Europe's established research ecosystem and pharmaceutical industry provide a strong foundation for continued investment in genomic technologies. However, adoption across different end-use settings can vary according to healthcare funding, regulatory frameworks, testing reimbursement, infrastructure availability, data governance requirements, and access to trained genetic and bioinformatics professionals.

Speak to an Analystto discuss market opportunities.

Europe Genetic Testing Market Regional Analysis

Due to the high prevalence of cancer among the population as well as the broad availability of diagnostic systems and consumables in Germany, Germany has the greatest market share. This is because Germany has the most options available to them.

The news articles that were published in January 2020 state that the Europe genetic testing market is exploding in the countries of Europe. The National Health Service in the United Kingdom is now being expanded to include genetic testing thanks to the United Kingdom's Genomic Medicine Service. In a similar vein, the Danes, by way of their National Genome Center, are striving toward a vision of customised treatment for the whole population. Genomic Medicine 2025, on the other hand, aims to integrate France's healthcare system with the country's scientific and business communities. It is consequently anticipated that the increasing efforts coming from the United Kingdom regarding genetic testing in Europe will drive the expansion of this region in the genetic testing market over the course of the projected period.

Whole genome sequencing (WGS) has been demonstrated to find new diagnoses for people with the greatest spectrum of rare diseases explored to date, as stated in the study that was published by the University of Manchester in November 2021. This could have enormous repercussions for the National Health Service. Furthermore, the study found that WGS was able to find new diagnoses for people with the greatest spectrum of rare diseases. It is anticipated that the increasing advantages of genetic testing in the United Kingdom for the detection of rare diseases will lead to an increased adoption of genetic testing in this area. As a result, the expansion of this market in the United Kingdom is anticipated to be driven by this growth.

It is anticipated that the Europe genetic testing market would expand at a healthy rate over the period covered by the projection. Despite this, the increasing prevalence of chronic illnesses along with the growing assistance from government organisations are important factors that are helping to level out the growth of the market.

According to estimates, the market for genetic testing in Germany is now expanding at a rate that is second only to that of France. The introduction of new laws regarding reimbursement by the government is contributing to an increase in the demand within this industry. The effort was made by Germany with the assistance of an insurance programme run by the German government in the nation. The availability of qualified researchers in laboratories to work on the development of novel approaches is another factor that is fully responsible for slowing the growth pace of the industry.

It is anticipated that there will be healthy growth in the market for genetic testing in Italy in the years to come as a result of the rising prevalence of infectious illnesses. In addition, there is a growing trend toward the promotion of high-quality treatment services, which is helping to drive demand in the market.

It is anticipated that the market for genetic testing in Spain will expand at a rate that is promising. Awareness and growing levels of disposable income in metropolitan areas are major elements that will contribute to market expansion.

Additionally, the particular market affecting elements and changes in regulation in the market locally that effect both the present and future trends of the market are included in the portion of the study that is dedicated to each nation. Some of the data points that are utilised to anticipate the market situation for different nations include an examination of the upstream and downstream value chain, technological trends, porter's five forces analysis, and case studies. When providing a forecast analysis of country data, other factors that are taken into consideration include the presence and availability of global brands as well as the challenges those brands face as a result of large or scarce competition from local and domestic brands, as well as the impact of domestic tariffs and trade routes.

List of Key and Emerging Players in Europe Genetic Testing Market